Trial Profile
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Cisplatin
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
- 27 Aug 2023 Planned End Date changed from 31 May 2023 to 1 Jan 2024.
- 27 Aug 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Jan 2024.